CGRP Antibodies Improve Quality of Life in Lithuanian Migraine Patients
CGRP monoclonal antibody treatment reduced monthly migraine days and improved quality of life in 41 Lithuanian patients over 6 months.
Quick Facts
What This Study Found
CGRP monoclonal antibody treatment reduced monthly migraine days and improved quality of life in patients with frequent migraines over a 6-month follow-up period.
Key Numbers
41 patients were included, all with 4 or more monthly migraine days lasting more than 3 months. Patients received fremanezumab 225 mg and were followed for 6 months.
How They Did This
Prospective observational study following 41 migraine patients receiving CGRP monoclonal antibody treatment at a university hospital in Lithuania.
Why This Research Matters
Frequent migraines can be debilitating, and many older preventive treatments have limited effectiveness. This real-world data adds to evidence that CGRP-targeting antibodies offer meaningful improvement for people who suffer from chronic migraines.
The Bigger Picture
Most CGRP antibody data comes from Western European and North American populations. This study adds evidence from Lithuania, confirming consistent effectiveness across different healthcare systems.
What This Study Doesn't Tell Us
This was a small pilot study with only 41 patients at a single hospital, without a placebo comparison group. Results may not generalize to other populations.
Questions This Raises
- ?Would response rates differ with erenumab or galcanezumab?
- ?How do Lithuanian patients compare to Western European cohorts?
Trust & Context
- Key Stat:
- Quality of life improved Beyond reducing migraine frequency, CGRP antibody treatment improved overall quality of life measures in this Lithuanian cohort
- Evidence Grade:
- Rated preliminary: small pilot study at a single hospital without placebo control. Provides proof-of-concept real-world data.
- Study Age:
- Published in 2024. First published data on CGRP antibody use from Lithuania.
- Original Title:
- The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.
- Published In:
- Acta medica Lituanica, 31(1), 81-91 (2024)
- Database ID:
- RPEP-09143
Evidence Hierarchy
Frequently Asked Questions
Do CGRP antibodies work for frequent migraines?
Yes — in this and larger studies, CGRP antibodies consistently reduce monthly migraine days and improve quality of life in patients with frequent migraines.
What is fremanezumab?
A monthly self-injected antibody that blocks CGRP, a key molecule involved in migraine attacks. It prevents migraines rather than treating them acutely.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09143APA
Remenčiūtė, Monika; Varžaitytė, Greta; Žemgulytė, Gintarė. (2024). The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.. Acta medica Lituanica, 31(1), 81-91. https://doi.org/10.15388/Amed.2024.31.1.12
MLA
Remenčiūtė, Monika, et al. "The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.." Acta medica Lituanica, 2024. https://doi.org/10.15388/Amed.2024.31.1.12
RethinkPeptides
RethinkPeptides Research Database. "The Effect of Calcitonin Gene-Related Peptide Monoclonal Ant..." RPEP-09143. Retrieved from https://rethinkpeptides.com/research/remenciute-2024-the-effect-of-calcitonin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.